Oracle (NASDAQ: ORCL), Health Management Associates (NYSE: HMA), MetLife, Inc. (NYSE: MET), Micron Technology, Inc. (NYSE: MU) and NetSuite Inc. (NYSE: N) price targets adjusted by analysts.
Oracle (ORCL) had its price target lowered by Macquarie from $38.00 to $36.00. They have an “Outperform” rating on the company.
Health Management Associates (HMA) had its price target lowered by Ticonderoga from $12.00 to $10.00. They have a “Buy” rating on the company.
MetLife, Inc. (MET) had its price target lowered by Argus from $54.00 to $46.00. They have a “Buy” rating on the company.
Micron Technology, Inc. (MU) had its price target lowered by Wedbush from $12.50 to $9.00. They have an “Outperform” rating on the company.
NetSuite Inc. (N) had its price target lowered by Feltl & Co. from $42.00 to $36.00. They have a “Buy” rating on the company.
Showing posts with label Health Management. Show all posts
Showing posts with label Health Management. Show all posts
Friday, August 26, 2011
Monday, August 8, 2011
Dolby (DLB) (UEIC) (EXH) (NTSP) (HMA) Downgraded
Dolby Labs (NYSE: DLB), Universal Electronics Inc (NASDAQ: UEIC), Exterran Holdings, Inc. (NYSE: EXH), NetSpend (NASDAQ: NTSP) and Health Management Associates (NYSE: HMA) downgraded by analysts.
Dolby Labs (DLB) was downgraded by Collins Stewart from a “Buy” rating to a “Neutral” rating. They have a price target of $45.00 on the company.
Universal Electronics Inc. (UEIC) was downgraded by Deutsche Bank (NYSE:DB) from a “Buy” rating to a “Hold” rating.
Exterran Holdings, Inc. (EXH) was downgraded by Credit Suisse (NYSE:CS) from an “Outperform” rating to a “Neutral” rating.
NetSpend (NTSP) was downgraded by William Blair from an “Outperform” rating to a “Market Perform” rating.
Health Management Associates (HMA) was downgraded by Argus from a “Buy” rating to a “Hold” rating.
Dolby Labs (DLB) was downgraded by Collins Stewart from a “Buy” rating to a “Neutral” rating. They have a price target of $45.00 on the company.
Universal Electronics Inc. (UEIC) was downgraded by Deutsche Bank (NYSE:DB) from a “Buy” rating to a “Hold” rating.
Exterran Holdings, Inc. (EXH) was downgraded by Credit Suisse (NYSE:CS) from an “Outperform” rating to a “Neutral” rating.
NetSpend (NTSP) was downgraded by William Blair from an “Outperform” rating to a “Market Perform” rating.
Health Management Associates (HMA) was downgraded by Argus from a “Buy” rating to a “Hold” rating.
Friday, August 5, 2011
Hormel (HRL) (GGP) (HMA) (IFNNY) (IN) Downgraded
Hormel Foods Co. (NYSE: HRL), General Growth Properties, Inc (NYSE: GGP), Health Management Associates (NYSE: HMA), Infineon Technologies AG (NASDAQ: IFNNY) and Intermec Inc. (NYSE: IN) downgraded by analysts.
General Growth Properties, Inc. (GGP) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating.
Health Management Associates (HMA) was downgraded by CRT Capital to a “Buy” rating.
Hormel Foods Co. (HRL) was downgraded by Goldman Sachs (NYSE:GS) from a “Neutral” rating to a “Sell” rating.
Infineon Technologies AG (IFNNY) was downgraded by WestLB from a “Buy” rating to a “Neutral” rating.
Intermec Inc. (IN) was downgraded by Avian from a “Positive” rating to a “Neutral” rating.
General Growth Properties, Inc. (GGP) was downgraded by RBC Capital from an “Outperform” rating to a “Sector Perform” rating.
Health Management Associates (HMA) was downgraded by CRT Capital to a “Buy” rating.
Hormel Foods Co. (HRL) was downgraded by Goldman Sachs (NYSE:GS) from a “Neutral” rating to a “Sell” rating.
Infineon Technologies AG (IFNNY) was downgraded by WestLB from a “Buy” rating to a “Neutral” rating.
Intermec Inc. (IN) was downgraded by Avian from a “Positive” rating to a “Neutral” rating.
Monday, March 7, 2011
Health Management Associates (HMA) August Call Options
Shares in Health Management Associates (HMA) are down today, although activity in August contract call options suggests one strategist is positioning for a rally in HMA’s future.
The options player appears to have purchased a debit call spread, buying 1,300 calls at the August $11 strike for a premium of $0.75 each, and selling the same number of calls at the higher August $13 strike at a premium of $0.20 a-pop. The net cost of putting on the spread amounts to $0.55 per contract.
Thus, the bullish trader is poised to profit in the event the health care provider’s shares soar 15.4% over the existing price of $10.08 to surpass the effective breakeven point on the spread at $11.55 by August expiration day. The investor could walk away with maximum potential profits of $1.45 per contract if shares in Health Management Associates jump 29.9% to trade above $13.00 ahead of expiration.
Health Management was trading at $10.08, falling $0.07, or 0.69 percent, as of 2:32PM EST.
The options player appears to have purchased a debit call spread, buying 1,300 calls at the August $11 strike for a premium of $0.75 each, and selling the same number of calls at the higher August $13 strike at a premium of $0.20 a-pop. The net cost of putting on the spread amounts to $0.55 per contract.
Thus, the bullish trader is poised to profit in the event the health care provider’s shares soar 15.4% over the existing price of $10.08 to surpass the effective breakeven point on the spread at $11.55 by August expiration day. The investor could walk away with maximum potential profits of $1.45 per contract if shares in Health Management Associates jump 29.9% to trade above $13.00 ahead of expiration.
Health Management was trading at $10.08, falling $0.07, or 0.69 percent, as of 2:32PM EST.
Wednesday, December 15, 2010
Health Management (NYSE:HMA) Revenue Growth, EBITDA Progressing
Health Management (NYSE:HMA) revenue growth and EBITDA continue to progress nicely, and Barclays (NYSE:BCS) raised their price on the acute care hospital chain.
Barclays said, "HMA has shown continued signs of progress with better-than-expected revenue growth and EBITDA. Overall revenues have been better than expected, due to higher-than-expected revenue per adjusted admission growth. With the revenue upside, EBITDA has been stronger than anticipated."
Barclays maintains an "Overweight" on Health Management, which closed Tuesday at $9.29, up $0.17, or 1.86 percent. They raised their price target on them from $10 to $11.
Barclays said, "HMA has shown continued signs of progress with better-than-expected revenue growth and EBITDA. Overall revenues have been better than expected, due to higher-than-expected revenue per adjusted admission growth. With the revenue upside, EBITDA has been stronger than anticipated."
Barclays maintains an "Overweight" on Health Management, which closed Tuesday at $9.29, up $0.17, or 1.86 percent. They raised their price target on them from $10 to $11.
Monday, November 22, 2010
Health Management (NYSE:HMA) Outperforming Industry in Revenue Growth
Health Management (NYSE:HMA) is in the middle of a major turnaround, leading the sector in revenue growth. Soleil Securities has maintained their "Buy" rating on them while raising their price target.
Soleil reported, "HMA is in the heart of its turnaround phase, outperforming the industry on revenue growth (solid surgical growth) and same-hospital margin expansion (incremental cost control), and is aggressively building its revenue base via attractively priced acquisitions. We continue to recommend purchase of HMA shares."
Earnings estimates for full year 2011 were raised from $0.67 to $0.72, and EBITDA from $782 million to $800 million.
Health Management closed up Friday at $8.67, gaining $0.05, or 0.58 percent. Soleil has a price target of $10 on them, raising it from $9.
Soleil reported, "HMA is in the heart of its turnaround phase, outperforming the industry on revenue growth (solid surgical growth) and same-hospital margin expansion (incremental cost control), and is aggressively building its revenue base via attractively priced acquisitions. We continue to recommend purchase of HMA shares."
Earnings estimates for full year 2011 were raised from $0.67 to $0.72, and EBITDA from $782 million to $800 million.
Health Management closed up Friday at $8.67, gaining $0.05, or 0.58 percent. Soleil has a price target of $10 on them, raising it from $9.
Subscribe to:
Posts (Atom)